You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pembrolizumab

Showing 1 - 25 of 747
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Thyroid Trial in Houston (Pembrolizumab)

Recruiting
  • Thyroid
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Biliary Tract Cancer Trial in Goyang-si, Seoul (SMT-NK inj.+Pembrolizumab, Pembrolizumab)

Recruiting
  • Biliary Tract Cancer
  • SMT-NK inj.+Pembrolizumab
  • Pembrolizumab
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • +2 more
Jun 28, 2022

Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Pembrolizumab coformulated with hyaluronidase
  • +6 more
  • (no location specified)
Jan 27, 2023

Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)

Not yet recruiting
  • Prostate Cancer Metastatic
  • Pembrolizumab
  • +2 more
  • (no location specified)
Sep 29, 2022

Triple Negative Breast Cancer Trial in Shanghai (Cisplatin, Nab-paclitaxel, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 18, 2022

Melanoma Trial (Dapansutrile, Pembrolizumab)

Not yet recruiting
  • Melanoma
  • (no location specified)
Jul 26, 2022

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
May 26, 2022

NSCLC, Melanoma Trial (IMM60, Pembrolizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Melanoma
  • (no location specified)
Jan 24, 2023

Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma Trial (Pembrolizumab)

Not yet recruiting
  • Muscle Invasive Bladder Carcinoma
  • +2 more
  • Pembrolizumab
  • (no location specified)
Jun 23, 2022

Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Apr 25, 2022

Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Mucosal Melanoma
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Sep 15, 2022

Tumors Trial (vibostolimab, pembrolizumab, pemetrexed)

Active, not recruiting
  • Neoplasms
  • vibostolimab
  • +6 more
  • (no location specified)
Apr 22, 2022

Solid Tumor Trial (SKB264, Pembrolizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Dec 8, 2022

Renal Cell Cancer Trial (Axitinib, Pembrolizumab)

Withdrawn
  • Renal Cell Cancer
  • (no location specified)
Jul 29, 2022

Colorectal Cancer Trial (Pembrolizumab)

Not yet recruiting
  • Colorectal Cancer
  • Pembrolizumab
  • (no location specified)
Apr 13, 2022

Gastric Cancer Trial in Seoul (Pembrolizumab)

Recruiting
  • Gastric Cancer
  • Pembrolizumab
  • Seoul, Korea, Republic of
    Samsung Medical Center
Dec 23, 2021

Tumors Trial (Favezelimab, Pembrolizumab, Oxaliplatin)

Active, not recruiting
  • Neoplasms
  • Favezelimab
  • +7 more
  • (no location specified)
Apr 11, 2022

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Pembrolizumab
  • +3 more
  • Boston, Massachusetts
  • +1 more
Feb 11, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Washington (BXCL701, Pembrolizumab)

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023

NSCLC Trial (Pembrolizumab, Docetaxel)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 18, 2022

Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)

Not yet recruiting
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • Eribulin Mesylate
  • Pembrolizumab
  • (no location specified)
Jan 31, 2023

Melanoma Trial in Norway (BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab)

Active, not recruiting
  • Melanoma
  • Bergen, Norway
  • +4 more
Aug 24, 2022

Locally Advanced Colorectal Cancer Trial (Capecitabine, Oxaliplatin, Bevacizumab)

Not yet recruiting
  • Locally Advanced Colorectal Cancer
  • (no location specified)
Oct 18, 2022

Classical Hodgkin Lymphoma Trial in Charlottesville (Pembrolizumab, Doxorubicin, Vinblastine)

Recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab
  • +4 more
  • Charlottesville, Virginia
    University of Virginia
Jul 27, 2022

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Aug 16, 2022